Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study.
Backeljauw P, Kanumakala S, Loche S, Schwab KO, Pfäffle RW, Höybye C, Lundberg E, Battelino T, Kriström B, Giemza T, Zouater H. Backeljauw P, et al. Among authors: zouater h. Horm Res Paediatr. 2021;94(3-4):133-143. doi: 10.1159/000515875. Epub 2021 Jul 7. Horm Res Paediatr. 2021. PMID: 34350858 Free PMC article. Clinical Trial.
Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
Pfäffle R, Bidlingmaier M, Kreitschmann-Andermahr I, Land C, Partsch CJ, Schwab KO, Sommer H, Backeljauw P, Kanumakala S, Loche S, Zouater H, Strasburger CJ. Pfäffle R, et al. Among authors: zouater h. Horm Res Paediatr. 2020;93(3):154-163. doi: 10.1159/000508190. Epub 2020 Aug 19. Horm Res Paediatr. 2020. PMID: 32814319 Free article. Clinical Trial.
PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope® (somatropin) treatment in children: update on the United States cohort.
Backeljauw P, Miller BS, Levy R, McCormick K, Zouater H, Zabransky M, Campbell K. Backeljauw P, et al. Among authors: zouater h. J Pediatr Endocrinol Metab. 2021 Feb 26;34(4):431-440. doi: 10.1515/jpem-2020-0360. Print 2021 Apr 27. J Pediatr Endocrinol Metab. 2021. PMID: 33647196 Free article.
Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort.
Iughetti L, Antoniazzi F, Giavoli C, Bona G, Aversa T, Greggio NA, Guazzarotti L, Minelli R, Perrone L, Persani L, Pozzobon G, Ragusa L, Stagi S, Tornese G, Zecchino C, Gallinari P, Zouater H, Fedeli P, Zucchini S. Iughetti L, et al. Among authors: zouater h. J Endocrinol Invest. 2021 Mar;44(3):493-503. doi: 10.1007/s40618-020-01331-4. Epub 2020 Jun 15. J Endocrinol Invest. 2021. PMID: 32557273
No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study.
Beck-Peccoz P, Höybye C, Murray RD, Simsek S, Zabransky M, Zouater H, Stalla G. Beck-Peccoz P, et al. Among authors: zouater h. BMC Endocr Disord. 2019 Dec 11;19(1):138. doi: 10.1186/s12902-019-0464-2. BMC Endocr Disord. 2019. PMID: 31829160 Free PMC article.
Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults).
Höybye C, Beck-Peccoz P, Murray RD, Simsek S, Stalla G, Strasburger CJ, Urosevic D, Zouater H, Johannsson G. Höybye C, et al. Among authors: zouater h. Pituitary. 2021 Aug;24(4):622-629. doi: 10.1007/s11102-021-01139-2. Epub 2021 Mar 20. Pituitary. 2021. PMID: 33742320 Free PMC article.
14 results